ATLANTHERA DRUG DISCOVERY COMPANY

Company Overview

Patented technology focusing on bone and joint diseases: selective bone or joint targeting delivery of API’s for indications in oncology, inflammation, infection and pain. Custom drug conjugation to innovative HBP vectors (hydroxybisphosphonate)

Privately held biopharmaceutical company created in 2011 and located in Nantes, France

MORE INFO ON THE COMPANY

Our Board

Executive Board

Ronan LE BOT, CEO & Founder
Viviane BERTRAND, CSO/COO
Maxim EGOROV, Project Leader in Chemistry

Scientific Board

Pr Dominique HEYMANN, University Hospital, Nantes & Honorary Pr of Bone Oncology, Sheffield, UK
Pr François GOUIN, University Hospital, Nantes & Lyon
Dr Françoise REDINI, University Hospital, Nantes
An expert team and international network of oncology and bone disease specialists

MORE INFO ON OUR BOARD

Our patents

WO 2022229576 /A1 20221103
Hydroxybisphosphonic derivatives of meloxicam for the treatment of inflammatory joint diseases.

WO 201607932/A1 20160526
Hydrosoluble hydroxybisphosphonic derivatives of doxorubicin.

WO 2012130911/A1 20121004
Bifunctional hydroxy-bisphosphonic acid derivatives.

WO 2009083614/A1 20090709
Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue.

WO 2009083613/A1 20090709
Method for synthesizing hydroxybisphosphonic acid derivatives.

MORE INFO ON THE PATENTS AND SCIENTIFIC PUBLICATIONS

Our pipeline

CANDIDATE: 12b80 / ODD status granted by EU
PHASE: end regulatory pre-clinical/CMC
INDICATION: Osteosarcoma (first step) and extend to bone metastases
NEXT STEPS: Clinical phase in humans.

CANDIDATE: 18A184
PHASE: POC in two moderate/severe rat models of OA
INDICATION: acute/severe and chronic osteoarthritis
NEXT STEPS: CMC and Pre-clinical development

CANDIDATE: Vectorized-VX-765
PHASE: early research
INDICATION: metastatic breast cancer
NEXT STEPS: POC in rodents models

EXPECTED COLLABORATIONS IN HUMAN / VETERINARY FIELDS:
LICENSING, ACQUISITION, PRECLINICAL DEVELOPMENT.
CONTACT US

Selective bone targeting, local drug release and improved therapeutic index.

Active Pharmaceutical Ingredient (API) – Vectorization of molecules with different functional groups – NCEs

Custom linkers

– Selective local drugs release (pH, enzymes, …)
– Modulation of drug’s LogP, solubility, transport, …

Innovative Bone Targeting Vectors

– Improved drug distribution Vectors
– Modulation of retention in the bone
– Modulation of antiresorptive action

API releasing group

– Key for API liberation
– Modulates API release rate and cleavage conditions

Engineering innovative HBP vectors for targeting bones and joints

OUR STORY

With strong internal capabilities in Chemistry and Biology, Atlanthera has built a unique R&D know-how in the vectorization of APIs through its innovative flagship technology «bifunctional HBP molecules» over the last 13 years

Development of specific and custom “linkers”
Development of new vectorized
APIs (bone and joints local sustained release)
Improved compliance to treatment
Repositioning of drugs already on the market, salvage of a drug that has been served a Clinical Hold order, find a new indication for a drug
Generation of new patentable entities
Reducing systemic toxicity/AEs

OUR COMMITMENT

We are a biotechnology company that develops new treatments for people with bone/joint diseases such as osteosarcoma, bone metastases from various primary cancers, inflammatory diseases such as arthritis and osteoarthritis, bone microbial such as osteomyelitis and septic arthritis.

We have developed a portfolio of new entities (Human and/or Veterinary use) that stand out from conventional therapies by targeting the active ingredient as closely as possible to the tissues to be treated (bone and/or joints), locally sustained and thus reducing systemic adverse effects.

Last news

October 202417 octobre 2024
October 2024 – Atlanthera announces the publication
June 202415 juin 2024
Atlanthera announces a research collaboration with the University of Sheffield to find new therapy against breast tumours and breast derived bone metastasis …
March 202415 mars 2024
At the occasion of the World Rare Disease Day , our team wants to make a meaningful impact on osteosarcoma and on those affected by rare diseases.

References

+33 251 789 876

linkedin.com/company/atlanthera

Contact our Team

« * » indique les champs nécessaires